Oncologists’ and urologists’ preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment
Most physicians in this study would recommend adjuvant therapy to a typical high-risk postnephrectomy RCC patient.
Authors
- Christine Poulos (ORCID: https://orcid.org/0000-0001-7810-3411)
- Rituparna Bhattacharya (ORCID: https://orcid.org/0000-0002-4505-6994)
- Cathy Anne Pinto (ORCID: https://orcid.org/0000-0002-7793-1706)
- Cooper Bussberg (ORCID: https://orcid.org/0000-0002-7854-3596)
- Kentaro Imai (ORCID: https://orcid.org/0009-0001-1246-5601)
- Shawna R. Calhoun (ORCID: https://orcid.org/0000-0003-2990-2369)
- Caroline Vass (ORCID: https://orcid.org/0000-0002-6385-2812)
- Kelley Myers (ORCID: https://orcid.org/0000-0002-0936-5677)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- RTI Health Solutions (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1080/14796694.2025.2464485
- Citations
- 3
- Primary Topic
- Patient-Provider Communication in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 8.45
Funders
- Merck
- American Society of Clinical Oncology